Start with landmark trials
Large, well-documented trials with posted estimates, confidence intervals and publications.
- REVEALIndependent statistical analysis of the phase 3 REVEAL trial of anacetrapib versus placebo in atherosclerotic cardiovascular disease, including trial design, time-to-event endpoints, log-rank analysis, rate ratios, confidence intervals, safety, and statistical interpretation.
- FOURIERIndependent statistical analysis of the FOURIER phase 3 trial of evolocumab versus placebo in subjects with elevated cardiovascular risk and dyslipidemia, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, and interpretation.
- COMPASSIndependent statistical analysis of the COMPASS phase 3 trial of rivaroxaban-based antithrombotic treatment in coronary or peripheral artery disease, including trial design, time-to-event endpoints, hazard ratios, safety outcomes, statistical methods, and interpretation.
- TRA 2P-TIMI 50Independent statistical analysis of TRA 2P-TIMI 50 (NCT00526474), including randomized trial design, time-to-event endpoints, Cox proportional-hazards methods, efficacy results, bleeding outcomes, post-hoc analyses, and statistical interpretation.
- ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.
- ARISTOTLEIndependent statistical analysis of ARISTOTLE (NCT00412984), including trial design, time-to-event endpoints, Cox proportional-hazards methodology, hazard ratios, confidence intervals, safety results, and statistical interpretation.
Explore by statistical method
Every trial page explains the methods behind its results. Pick a method to see it applied.
Browse by therapeutic area
Oncology
Phase 2 and 3 cancer trials, dominated by time-to-event endpoints: overall and progression-free survival, hazard ratios, stratified log-rank tests, and response rates.
Infectious Disease
Trials of vaccines, antivirals, antibiotics and prevention strategies, from HIV and hepatitis to influenza and COVID-19, with many non-inferiority designs.
Cardiovascular
Large outcome trials in heart failure, atrial fibrillation, coronary disease and stroke prevention, built around composite time-to-event endpoints.
Neurology
Trials in multiple sclerosis, Alzheimer's disease, migraine, epilepsy, Parkinson's disease and stroke, with relapse-rate, longitudinal and time-to-event analyses.
Psychiatry & Mental Health
Trials in depression, schizophrenia, bipolar disorder, anxiety and substance use, typically analyzed with mixed models for repeated measures.
Endocrinology & Metabolism
Diabetes, obesity and metabolic trials, from HbA1c and weight endpoints analyzed with ANCOVA and MMRM to cardiovascular outcome trials.
Respiratory
Asthma, COPD, pulmonary fibrosis and cystic fibrosis trials, including exacerbation-rate endpoints analyzed with negative binomial and Poisson models.
Nephrology & Urology
Chronic kidney disease, dialysis and urologic trials, with kidney-function slopes and composite renal outcomes.
Hematology
Trials in anemia, hemophilia, sickle cell disease and blood cancers, spanning response rates, bleeding rates and survival endpoints.
Immunology & Rheumatology
Rheumatoid arthritis, psoriasis, lupus and allergic-disease trials, often built on responder endpoints and categorical analyses.
Gastroenterology & Hepatology
Inflammatory bowel disease, liver disease and other digestive-disorder trials, with remission endpoints and categorical comparisons.
Women's Health & Pregnancy
Trials in pregnancy, contraception and gynecologic conditions, spanning binary outcomes and time-to-event analyses.
Critical Care & Injury
Sepsis, trauma, shock and critical-illness trials, typically centered on mortality and organ-support outcomes.